---
title: 科学家希望用抗癌药物治疗肠道疾病
date: 2024-06-05T15:28:15.778Z
description: ‘Gene desert’ research boosts knowledge of chronic disease mechanisms and promises to unlock novel therapies
tags: 
- world
author: ft
---

[原文链接](https://ft.com/content/06a8ea18-2c92-4606-9b95-e69f614c5c10)

科学家希望用抗癌药物治疗肠道疾病

# 科学家发现一种癌症药物可能能治疗炎症性肠病

**新闻摘要：** 科学家们在研究与炎症性肠病相关的基因沙漠和生物途径后，确定了一种癌症药物作为炎症性肠病（IBD）的潜在治疗方法。由英国弗朗西斯·克里克研究所、UCL 和伦敦帝国理工学院的科学家们进行的这项研究发表在《自然》杂志上。

**要点：**
- 研究人员探索了一个“基因沙漠”——没有编码蛋白的基因组区域——以了解 IBD 的机制。
- 该研究侧重于增强 ETS2 基因的增强子，该基因增加参与 IBD 的巨噬细胞中的炎症反应。
- MEK 抑制剂是一类用于黑色素瘤和神经纤维瘤治疗的癌症药物，发现它们可以降低 IBD 患者肠道样本中巨噬细胞的炎症反应。
- 由于之前对安全性和有效性的研究，这些现有药物的潜在应用可能具有经济优势。

**影响：**
- 这一发现可能导致用于治疗 IBD 的新型疗法，这是一种影响全球数百万人、治疗选择有限的慢性疾病。
- MEK 抑制剂需要临床试验来证明其对 IBD 的有效性，同时要考虑潜在的副作用，如呕吐和高血压。
- 重新部署现有已批准的药物可能因之前对安全性和有效性的研究而带来健康和经济效益。

---

 **Article Summary:** Scientists have identified a cancer drug as a potential treatment for inflammatory bowel disease (IBD), based on research into gene deserts and biological pathways related to the condition. The study, conducted by scientists at the UK's Francis Crick Institute, UCL, and Imperial College London, was published in Nature.

**Key Points:**
- Researchers explored a "gene desert" - a genome region without protein-coding genes - to uncover new insights into IBD mechanisms.
- The study focused on an enhancer that boosted the ETS2 gene, which increases inflammatory activity in macrophages involved in IBD.
- MEK inhibitors, a group of cancer drugs used for melanoma and neurofibroma treatment, were found to lower inflammamoes in both macrophages and gut samples from IBD patients.
- The potential use of these existing medicines could offer financial advantages due to prior research on safety and efficacy.

**Implications:**
- This discovery may lead to novel therapies for treating IBD, a chronic condition affecting millions worldwide with limited treatment options.
- MEK inhibitors would require clinical trials to prove their effectiveness for IBD, considering potential side effects such as vomiting and hypertension.
- The redeployment of existing approved drugs could provide both health and financial benefits due to prior research on safety and efficacy.

[Source Link](https://ft.com/content/06a8ea18-2c92-4606-9b95-e69f614c5c10)

